Invivyd has introduced VYD2311, a next-generation monoclonal antibody (mAb) that is 99% structurally identical to Pemgarda but features key molecular changes for increased potency1.
Pemgarda previously received FDA emergency use authorization for pre-exposure prevention of COVID-19 in moderately to severely immunocompromised adults and adolescents15.
Phase 1/2 trial data show VYD2311 is well tolerated across intravenous, intramuscular, and subcutaneous routes, with only mild adverse injection-site reactions12.
VYD2311 demonstrated a longer in-vivo half-life and “substantially greater” serum concentrations at six months compared to Pemgarda1.
Invivyd claims VYD2311’s long half-life could allow for durable protection against symptomatic COVID-19, potentially lasting multiple quarters—offering more sustained protection than current COVID vaccines, which exhibit rapidly waning benefit1.
High-dose IV administration of VYD2311 may also offer long-term viral suppression for COVID-19 treatment1.
Sources:
1. https://www.fiercebiotech.com/biotech/invivyd-claims-pemgarda-mab-follow-could-hold-its-own-against-covid-vaccines
2. https://www.biospace.com/press-releases/invivyd-announces-positive-full-phase-1-2-clinical-data-for-vyd2311-a-next-generation-covid-19-monoclonal-antibody-for-potential-use-as-a-non-vaccine-preventative-and-for-treatment-of-active-infection
5. https://www.globenewswire.com/news-release/2025/05/27/3088481/0/en/Invivyd-Announces-Publication-of-Landmark-CANOPY-Phase-3-PEMGARDA-pemivibart-Clinical-Trial-Results-Underscore-Strong-Efficacy-of-Monoclonal-Antibodies-in-Preventing-COVID-19-in-a-.html